IRONWOOD PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense, after Tax
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Share-based Payment Arrangement, Expense, after Tax of $2.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for the quarter ending 2026-06-30 was $2.39M, a 40.13% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for the quarter ending 2026-03-31 was $5.20M, a 181.15% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for the quarter ending 2025-12-31 was -$1.26M, a 131.49% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for the quarter ending 2025-09-30 was $3.27M, a 56.36% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for fiscal 2025 was $14.73M, a 44.28% decline from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for fiscal 2024 was $26.44M, a 53.28% decline from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for fiscal 2023 was $56.59M, a 122.76% increase from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. share-based payment arrangement, expense, after tax for fiscal 2022 was $25.40M, a 14.02% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 3 month as first filed | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 6 month as first filed | Share-based Payment Arrangement, Expense, after Tax 9 month | Share-based Payment Arrangement, Expense, after Tax 12 month | Share-based Payment Arrangement, Expense, after Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.39M 10-Q · filed 2026-08-06 | $7.59M 10-Q · filed 2026-08-06 | $6.33M derived: sum of 3 quarters · filed 2026-08-06 | $9.60M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $5.20M 10-Q · filed 2026-05-07 | $3.94M derived: sum of 2 quarters · filed 2026-05-07 | $7.21M derived: sum of 3 quarters · filed 2026-05-07 | $11.20M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.01M derived: sum of 2 quarters · filed 2026-02-26 | $6.00M derived: sum of 3 quarters · filed 2026-08-06 | $14.73M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $3.27M 10-Q · filed 2025-11-10 | $7.26M derived: sum of 2 quarters · filed 2026-08-06 | $15.99M 10-Q · filed 2025-11-10 | $13.12M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $3.99M 10-Q · filed 2026-08-06 | $12.72M 10-Q · filed 2026-08-06 | $9.85M derived: sum of 3 quarters · filed 2026-08-06 | $17.34M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $1.85M 10-Q · filed 2026-05-07 | $5.86M derived: sum of 2 quarters · filed 2026-05-07 | $13.35M derived: sum of 3 quarters · filed 2026-05-07 | $21.27M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.49M derived: sum of 2 quarters · filed 2026-02-26 | $19.42M derived: sum of 3 quarters · filed 2026-02-26 | $26.44M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $7.49M 10-Q · filed 2025-11-10 | $15.41M derived: sum of 2 quarters · filed 2025-11-10 | $22.43M 10-Q · filed 2025-11-10 | $30.24M derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2024-06-30 | $7.92M 10-Q · filed 2025-08-11 | $14.94M 10-Q · filed 2025-08-11 | $22.75M derived: sum of 3 quarters · filed 2025-08-11 | $29.81M derived: sum of 4 quarters · filed 2025-08-11 | |||
| 2024-03-31 | $7.02M 10-Q · filed 2025-05-12 | $14.83M derived: sum of 2 quarters · filed 2025-05-12 | $21.89M derived: sum of 3 quarters · filed 2025-05-12 | $56.78M derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | $7.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $14.87M derived: sum of 2 quarters · filed 2025-03-31 | $49.76M derived: sum of 3 quarters · filed 2025-03-31 | $56.59M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $7.06M 10-Q · filed 2024-11-07 | $41.95M derived: sum of 2 quarters · filed 2024-11-07 | $48.78M 10-Q · filed 2024-11-07 | $53.70M derived: sum of 4 quarters · filed 2025-03-31 | |||
| 2023-06-30 | $34.89M 10-Q · filed 2024-08-08 | $41.73M 10-Q · filed 2024-08-08 | $46.65M derived: sum of 3 quarters · filed 2025-03-31 | $54.88M derived: sum of 4 quarters · filed 2025-03-31 | |||
| 2023-03-31 | $6.83M 10-Q · filed 2024-05-09 | $7.43M 10-Q · filed 2023-05-04 | $11.76M derived: sum of 2 quarters · filed 2025-03-31 | $19.99M derived: sum of 3 quarters · filed 2025-03-31 | $26.31M derived: sum of 4 quarters · filed 2025-03-31 | ||
| 2022-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $13.15M derived: sum of 2 quarters · filed 2025-03-31 | $19.48M derived: sum of 3 quarters · filed 2025-03-31 | $25.40M 10-K · filed 2025-03-31 | $28.69M 10-K · filed 2023-02-16 | ||
| 2022-09-30 | $8.23M 10-Q · filed 2023-11-09 | $14.55M derived: sum of 2 quarters · filed 2023-11-09 | $20.48M 10-Q · filed 2023-11-09 | $26.01M derived: sum of 4 quarters · filed 2024-02-16 | |||
| 2022-06-30 | $6.32M 10-Q · filed 2023-08-09 | $6.88M 10-Q · filed 2022-08-04 | $13.13M 10-Q · filed 2023-08-09 | $12.25M 10-Q · filed 2022-08-04 | $17.78M derived: sum of 3 quarters · filed 2024-02-16 | $23.99M derived: sum of 4 quarters · filed 2024-02-16 | |
| 2022-03-31 | $5.37M 10-Q · filed 2023-05-04 | $11.46M derived: sum of 2 quarters · filed 2024-02-16 | $17.66M derived: sum of 3 quarters · filed 2024-02-16 | $22.25M derived: sum of 4 quarters · filed 2024-02-16 | |||
| 2021-12-31 | $6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $12.30M derived: sum of 2 quarters · filed 2024-02-16 | $16.89M derived: sum of 3 quarters · filed 2024-02-16 | $22.28M 10-K · filed 2024-02-16 | |||
| 2021-09-30 | $6.21M 10-Q · filed 2022-11-03 | $10.79M derived: sum of 2 quarters · filed 2022-11-03 | $16.19M 10-Q · filed 2022-11-03 | ||||
| 2021-06-30 | $4.59M 10-Q · filed 2022-08-04 | $9.98M 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | $5.40M 10-Q · filed 2022-05-05 | ||||||
| 2020-12-31 | $31.18M 10-K · filed 2023-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |